论文部分内容阅读
目的 :探讨血脂康对 2型糖尿病患者血小板活化功能及糖脂代谢的影响。方法 :将 6 5例 2型糖尿病患者分为高脂血症组 (31例 )和正常血脂组 (34例 ) ,测定患者的血小板表面α-颗粒膜蛋白 (GMP - 14 0 )、血小板血栓烷素B2 (TXB2 )及血糖、血清胰岛素水平 ,计算胰岛素敏感指数 (ISI) ,对伴有高脂血症者用血脂康治疗 8周后重复测定上述指标。结果 :伴高脂血症者的GMP - 14 0、TXB2 及血甘油三酯 (TG)、血总胆固醇 (TC)、低密度脂蛋白 -胆固醇 (LDL -C)较正常血脂者明显升高 (P <0 0 5～ 0 0 1) ,ISI及高密度脂蛋白 -胆固醇 (HDL -C)明显降低 (P <0 0 1) ;伴高脂血症者经过血脂康治疗 8周后TG、TC、LDL -C及GMP - 14 0、TXB2 较治疗前降低 (P <0 0 5～ 0 0 1) ,HDL -C及ISI较治疗前明显升高 (P <0 0 5 )。结论 :血脂康对伴高脂血症的 2型糖尿病患者在调脂治疗的同时可降低血小板活性 ,改善胰岛素抵抗
Objective: To investigate the effect of Xuezhikang on platelet activation and glucose and lipid metabolism in type 2 diabetic patients. Methods Sixty - five patients with type 2 diabetes were divided into two groups: hyperlipidemia group (n = 31) and normolipidemia group (n = 34). The level of platelet membrane protein (GMP - 140), thromboxane (TXB2) and blood glucose, serum insulin levels, calculate the insulin sensitivity index (ISI), with hyperlipidemia were treated with Xuezhikang 8 weeks after the above measurements were repeated. Results: The levels of GMP - 140, TXB2 and triglyceride (TG), total cholesterol (TC) and low density lipoprotein - cholesterol (LDL - C) in patients with hyperlipidemia were significantly higher than those in normal subjects (P <0.01), ISI and HDL-C (P <0.01). After treatment of Xuezhikang with hyperlipidemia for 8 weeks, TG, TC , LDL-C and GMP-140, TXB2 were lower than those before treatment (P <0.05-0.01), while HDL-C and ISI were significantly higher than those before treatment (P <0.05). Conclusion: Xuezhikang on type 2 diabetes mellitus with hyperlipidemia can reduce platelet activity and improve insulin resistance